Enodia Therapeutics

Enodia

This company develops small-molecule therapies that degrade disease-causing proteins at the point of synthesis for patients with cancer and inflammatory diseases.

Kymera Therapeutics

This biotechnology company develops small molecule medicines that degrade disease-causing proteins for patients with cancer and immune-inflammatory diseases.

Biotheryx

The company develops protein degrader medicines for patients with cancer and inflammatory diseases.

Amphista Therapeutics

This company develops targeted protein degradation medicines to treat patients with cancer and other diseases.

ProteoValent Therapeutics

This company develops targeted protein degrader therapies for cancer and haematology patients.

Tactile Therapeutics

This company develops small molecule drugs using targeted protein degradation to treat neurodegenerative diseases and cancer for pharmaceutical partners and patients.

Lycia Therapeutics

The company develops extracellular protein-degrading therapeutics for patients with autoimmune, inflammatory and allergic diseases.

Nurix Therapeutics

This company develops targeted protein degradation therapies to treat patients with cancer and autoimmune diseases.